VIMTA LABS LTD.-$ - 524394 - Closure of Trading Window
Closure of Trading Window from 1st January 2024 till 48 hours after declaration of unaudited financial result''s of Q3.31-12-2023
31-12-2023
VIMTA LABS LTD.-$ - 524394 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meet on 11.12.2023 with Systamatix Group -Investor Conference at The Capital Building - BKC Mumbai06-12-2023
VIMTA LABS LTD.-$ - 524394 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of 18018 Equity Shares under Employee Stock Option Plan 2021.17-11-2023
VIMTA LABS LTD.-$ - 524394 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Praveen Vasireddi17-11-2023
VIMTA LABS LTD.-$ - 524394 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the Q2-2024 earning/investor call held on 30th October 2023.03-11-2023
VIMTA LABS LTD.-$ - 524394 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Q2 Newspaper Publication.31-10-2023
VIMTA LABS LTD.-$ - 524394 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of the Q2-2024 earnings/investor call held on 30th October 2023.30-10-2023
Q2FY24 Quarterly & H1FY24 Bi-Annual Result Announced for Vimta Labs Ltd.
Healthcare Services company Vimta Labs announced Q2FY24 & H1FY24 results: Total Income for Q2FY24 was at Rs 754 million a de-growth of 6.4% YoY EBITDA for Q2FY24 was Rs 179 million a decline of 31.4% YoY; EBITDA margin was at 23.8% Total Income for H1FY24 was at Rs 1,595 million a de-growth of 0.7% YoY EBITDA for H1FY24 was Rs 432 million a decline of 15.3% YoY; EBITDA margins at 27.1% Cash and Cash equivalents at Rs 262 million as of September 30, 2023 Cash flow From Operations at Rs 268 million for H1FY24; H1FY24 Capex at Rs 421 million Debt to Equity ratio 0.07 Commenting on results, Harita Vasireddi, Managing Director, Vimta Labs, said, “The downtrend in our income has primarily stemmed from the Pharma and Food business, which saw decreased demand and lower volumes respectively. Conversely, our E&E; business continues to perform well, with Environment and Diagnostics remained stable. Given the headwinds from the broader economic uncertainties, we acknowledge the external challenges. However, our ongoing dialogues with clients along with the stability provided by our long-term contracts and revenue visibility for the H2FY24 keeps me optimistic of delivering growth in FY24.” Result PDF30-10-2023
VIMTA LABS LTD.-$ - 524394 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Q2 & H1 FY 24 Results30-10-2023